A Case of Biopharmaceutical-Induced Catatonia and the Implication of a Novel Mechanism

J ECT. 2020 Sep;36(3):e29-e30. doi: 10.1097/YCT.0000000000000650.

Abstract

Catatonia can be described structurally as a motor dysregulation syndrome with a concomitant behavioral component. However, despite its initial recognition nearly 150 years ago, the exact pathophysiological causes underlying this syndrome are still somewhat unknown and are potentially variable. This report reviews a case of a patient with multiple catatonic episodes precipitated by the use of an immunomodulator medication, and in doing so suggests a possible mechanism speaking to the immune system's role in the etiology of some cases of catatonia.

Publication types

  • Case Reports

MeSH terms

  • Biological Products / adverse effects*
  • Catatonia / chemically induced*
  • Catatonia / therapy*
  • Electroconvulsive Therapy*
  • Electroencephalography
  • Etanercept / adverse effects*
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Young Adult

Substances

  • Biological Products
  • Etanercept